发明授权
- 专利标题: Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
- 专利标题(中): 羧酸化合物和含有与活性成分相同的药物组合物
-
申请号: US10572578申请日: 2004-09-16
-
公开(公告)号: US07601712B2公开(公告)日: 2009-10-13
- 发明人: Atsushi Naganawa , Maki Iwahashi , Atsushi Kinoshita , Atsushi Shimabukuro , Seiji Ogawa , Koji Yano , Kaoru Kobayashi , Yutaka Okada , Yoko Kishida , Shouji Kawauchi , Kohki Tsukamoto , Yoko Matsunaga , Fumio Nambu
- 申请人: Atsushi Naganawa , Maki Iwahashi , Atsushi Kinoshita , Atsushi Shimabukuro , Seiji Ogawa , Koji Yano , Kaoru Kobayashi , Yutaka Okada , Yoko Kishida , Shouji Kawauchi , Kohki Tsukamoto , Yoko Matsunaga , Fumio Nambu
- 申请人地址: JP Osaka
- 专利权人: Ono Pharmaceutical Co., Ltd.
- 当前专利权人: Ono Pharmaceutical Co., Ltd.
- 当前专利权人地址: JP Osaka
- 代理机构: Sughrue Mion, PLLC
- 优先权: JP2003-325198 20030917; JP2004-101863 20040331
- 国际申请: PCT/JP2004/013983 WO 20040916
- 国际公布: WO2005/028455 WO 20050331
- 主分类号: A61K31/535
- IPC分类号: A61K31/535 ; A61K31/36 ; A61K31/34 ; A61K31/335 ; C07D265/36 ; C07D317/44 ; C07D307/00 ; C07D319/14
摘要:
A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.
公开/授权文献
信息查询